PAR - Par Drugs & Che.
📢 Recent Corporate Announcements
Par Drugs and Chemicals reported a stellar performance for Q3 FY26, with revenue from operations growing 37.2% YoY to ₹29.34 crore. Net profit witnessed an exceptional surge of approximately 730% YoY, rising from ₹0.58 crore to ₹4.80 crore. On a sequential basis, the company maintained steady momentum with net profit increasing by 16.2% compared to Q2 FY26. The company continues to operate as a pure-play API manufacturer, showing significant margin expansion as profit growth vastly outpaced revenue growth.
- Revenue from operations increased by 37.2% YoY to ₹2,933.95 Lakhs from ₹2,138.11 Lakhs.
- Net Profit skyrocketed to ₹479.72 Lakhs in Q3 FY26 compared to ₹57.80 Lakhs in Q3 FY25.
- Earnings Per Share (EPS) improved significantly to ₹3.90 from ₹0.47 in the year-ago period.
- Nine-month (9M FY26) net profit stands at ₹1,225.49 Lakhs, nearly matching the full-year FY25 profit of ₹1,335.79 Lakhs in just three quarters.
- Total expenses for the quarter were ₹2,422.30 Lakhs, with cost of materials consumed accounting for ₹1,211.91 Lakhs.
Par Drugs and Chemicals reported a robust performance for Q3 FY26, with revenue from operations growing 37.2% year-on-year to ₹29.34 crore. The company's net profit witnessed a massive surge of approximately 730% YoY, rising from ₹0.58 crore to ₹4.80 crore, driven by strong operational performance. On a sequential basis (QoQ), revenue grew by 2.4% while net profit increased by 16.2%. The company continues to operate as a pure-play API manufacturer with a significantly improved EPS of ₹3.90 for the quarter.
- Revenue from operations increased 37.2% YoY to ₹2,933.95 Lakhs from ₹2,138.11 Lakhs.
- Net Profit skyrocketed to ₹479.72 Lakhs compared to ₹57.80 Lakhs in the same quarter last year.
- Earnings Per Share (EPS) improved significantly to ₹3.90 from ₹0.47 in the year-ago period.
- Profit Before Tax (PBT) for the nine-month period ended Dec 2025 reached ₹1,647.00 Lakhs.
- Finance costs remained exceptionally low at ₹1.48 Lakhs for the quarter, indicating a strong balance sheet.
Par Drugs and Chemicals reported an exceptionally strong performance for the quarter ended December 31, 2025, with Net Profit jumping over 7-fold to ₹479.72 Lakh from ₹57.80 Lakh in the previous year. Revenue from operations grew by 37.2% YoY to ₹2,933.95 Lakh, indicating robust demand and improved operational efficiency. The company's profitability margins saw a massive expansion, with Profit Before Tax (PBT) rising from ₹77.24 Lakh to ₹644.20 Lakh YoY. Sequentially, the company also showed steady growth in both top-line and bottom-line compared to the September 2025 quarter.
- Net Profit (PAT) skyrocketed by 730% YoY to ₹479.72 Lakh from ₹57.80 Lakh.
- Revenue from operations increased 37.2% YoY to ₹2,933.95 Lakh compared to ₹2,138.11 Lakh.
- Earnings Per Share (EPS) improved significantly to ₹3.90 from ₹0.47 in the year-ago period.
- Profit Before Tax (PBT) stood at ₹644.20 Lakh, an 8.3x increase over the previous year's ₹77.24 Lakh.
- Nine-month (9M FY26) PAT reached ₹1,225.49 Lakh, nearing the total FY25 full-year profit of ₹1,335.79 Lakh.
Par Drugs and Chemicals reported a robust performance for the quarter ended December 31, 2025, with revenue from operations growing 37.2% year-on-year to ₹29.34 crore. The net profit witnessed a massive jump of approximately 730%, rising from ₹0.58 crore in the previous year's quarter to ₹4.80 crore. On a sequential basis, revenue increased from ₹28.66 crore in Q2 FY26, and PAT rose from ₹4.13 crore. The nine-month performance also shows steady growth with a total PAT of ₹12.25 crore.
- Revenue from operations increased 37.2% YoY to ₹2,933.95 Lakhs in Q3 FY26.
- Net Profit (PAT) skyrocketed to ₹479.72 Lakhs from ₹57.80 Lakhs in the same quarter last year.
- Quarterly Earnings Per Share (EPS) improved significantly to ₹3.90 from ₹0.47 YoY.
- Nine-month (9M) PAT stood at ₹1,225.49 Lakhs, showing a 4.7% growth over the previous year's 9M period.
- Finance costs remained extremely low at ₹1.48 Lakhs for the quarter, indicating a debt-light balance sheet.
Par Drugs and Chemicals Limited has informed the National Stock Exchange about a change in the Investor Education and Protection Fund Authority (IEPFA) helpline number. The new official number for investor queries and claims is 14453. This update follows a directive from the IEPFA, rendering all previously circulated contact numbers deactivated. This is a routine administrative disclosure to ensure shareholders have the correct contact information for IEPF-related matters.
- The official IEPFA helpline number has been updated to 14453
- All previous contact numbers for the authority have been deactivated as of January 23, 2026
- The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015
Par Drugs and Chemicals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended December 31, 2025. The certificate, issued by MUFG Intime India Private Limited, confirms that dematerialization requests were processed and physical certificates were mutilated and cancelled. This filing ensures that the company is in compliance with depository regulations and that the register of members has been updated accordingly. This is a standard administrative procedure for listed companies in India.
- Compliance certificate submitted for the quarter ended December 31, 2025
- Registrar MUFG Intime India Private Limited confirmed processing of all demat requests
- Physical share certificates were mutilated and cancelled after due verification
- Register of members updated with depository names within prescribed timelines
Par Drugs and Chemicals Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of the company's unaudited financial results for the quarter and nine months ending December 31, 2025. The trading window will remain closed for all designated persons and their relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be announced at a later time.
- Trading window closure effective from Thursday, January 1, 2026.
- Closure relates to the financial results for the quarter and nine months ended December 31, 2025.
- Window will reopen 48 hours after the official declaration of the financial results.
- Applies to all designated persons, employees, and their immediate relatives as per SEBI regulations.
The National Stock Exchange (NSE) has appointed Kunvarji Finstock Private Limited to provide a fairness opinion regarding Par Drugs and Chemicals Limited, effective December 12, 2025. This move follows an Ex-Parte Interim Order issued by SEBI on September 15, 2025 (Order No. WTM/KV/CFID/CFID-SEC4/31660/2025-26). The company currently reports no quantifiable impact on its financial or operational activities due to this specific appointment. However, the requirement for a fairness opinion under a SEBI interim order suggests ongoing regulatory scrutiny that investors must track closely.
- NSE appointed Kunvarji Finstock Private Limited as merchant banker on Dec 12, 2025
- Action taken in response to SEBI Ex-Parte Interim Order dated Sept 15, 2025
- The merchant banker will provide a fairness opinion as directed by SEBI
- Company states no immediate monetary impact on financial or operational activities
Financial Performance
Revenue Growth by Segment
The API segment, which currently contributes over 99% of total revenue, grew 5.6% YoY in FY25. Revenue for the quarter ended September 30, 2025, was INR 28.66 Cr.
Profitability Margins
Operating Profit Margin declined from 34.42% to 28.74% (a 16.51% decrease) in FY25. Net Profit Margin softened from 20.41% to 17.75% (a 13.02% decrease) due to raw material and operating cost inflation.
EBITDA Margin
EBITDA margin declined to 21.36% in FY25 from 24.00% in FY24. EBITDA contracted 6.0% YoY due to input cost inflation affecting core profitability.
Capital Expenditure
The company has committed a total capital expenditure of INR 95 Cr for strategic diversification, including INR 27 Cr for Real Estate, INR 27 Cr for Clean Energy, and INR 41 Cr for Capital Market Ventures.
Credit Rating & Borrowing
The company maintains a Debt-Equity Ratio of 0%, indicating it is debt-free. Interest coverage ratio is 0 as there is no significant long-term debt.
Operational Drivers
Capacity Expansion
The company approved a slump sale of its primary API business unit (99% of revenue) to pivot into new sectors. Planned investments include INR 27 Cr in Real Estate and INR 27 Cr in Clean & Renewable Energy.
Raw Material Costs
Cost of materials consumed was INR 10.54 Cr for the quarter ended September 2025, representing 36.7% of revenue. Input cost inflation led to a 6.0% contraction in EBITDA.
Strategic Growth
Growth Strategy
The company is executing a strategic pivot from its 99% revenue-contributing API business into three new verticals: Real Estate & Construction, Clean & Renewable Energy, and Capital Market Ventures. This INR 95 Cr investment strategy aims to align with 'Vision India @ 2047' and provide stable, countercyclical cash flows.
Products & Services
Currently sells Active Pharmaceutical Ingredients (API). Future products will include Real Estate construction units, Renewable Energy generation, and Capital Market services.
Brand Portfolio
PAR Drugs and Chemicals Limited.
New Products/Services
New services include Real Estate & Construction, Clean & Renewable Energy, and Capital Market Ventures, supported by a committed INR 95 Cr investment.
Market Expansion
Strategic diversification into resilient domestic sectors to reduce dependence on volatile global pharmaceutical cycles.
Strategic Alliances
The company entered into a slump sale agreement for its primary business unit, involving significant management judgment and related party transaction valuations.
External Factors
Industry Trends
The API industry is facing an evolving risk profile and high volatility. The company is positioning itself for the future by diversifying into sectors aligned with India's long-term development priorities (Vision India @ 2047).
Competitive Moat
The company is transitioning from a volatile API-based moat to a diversified multi-sector model to ensure sustainable long-term growth and stable cash flows.
Macro Economic Sensitivity
Highly sensitive to input cost inflation and global pharmaceutical cycles, which caused a 2.64 percentage point decline in EBITDA margins in FY25.
Geopolitical Risks
Exposure to volatile global pharma cycles is a primary risk, being mitigated by pivoting toward domestic-focused sectors like Indian real estate and energy.
Regulatory & Governance
Industry Regulations
Operations are governed by Ind AS 108 (Operating Segments), the Companies Act 2013, and ICAI's internal financial controls framework.
Environmental Compliance
The company continuously monitors and aligns operations with global ESG standards.
Taxation Policy Impact
The effective tax rate for the quarter ended September 2025 was approximately 25.6%, with INR 1.42 Cr in current tax on INR 5.55 Cr profit before tax.
Legal Contingencies
There have been no qualifications or adverse remarks in the Companies (Auditor’s Report) Order (CARO) reports for the audited periods.
Risk Analysis
Key Uncertainties
The primary uncertainty is the execution risk associated with transitioning from a 99% revenue-contributing API business to three entirely new business segments.
Technology Obsolescence Risk
The company has implemented accounting software with audit trail (edit log) facilities since April 1, 2023, to ensure financial reporting integrity.